If you’re planning on filing your federal income tax return in the next few days, you’re not alone: statistically, about a quarter of all returns are mailed in the last week of tax season. No matter how close to the wire you get, as long as your return is postmarke
People protest in front of Ocwen's offices. (Photo by Joe Raedle/Getty Images)
Billionaire Secretary of Commerce Wilbur Ross spent nearly two years on Ocwen Financial's board of directors after selling Homeward Residential to the once soaring St. Croix, Virgin Islands-based mortgage servic
Dear Evan Hansen of铿cially opened at the Music Box Theater on Dec. 4, moving to Broadway after a hugely successful run at the Second Stage Theater in New York earlier this year. With an impressive creative team, a bold, original new story and a wave of good buzz behind it, Dear Evan Hansen may become the next Broadway sensation and the season’s breakout hit.
American Express (AXP) is stuck between a rock and a hard place. As it battles MasterCard (MA) and Visa (V), American Express can either try to match their rewards–which will damage its returns–or stand its ground, which will make it hard to compete. Evercore ISI’s David Togut and team explain:
Credit card rewards continue to spiral skywards asAmerican....More>>>
On Thursday, our Under the Radar Moversnewslettersuggested suggested small cap employment services stockOn Assignment, Inc (NYSE: ASGN) as a short trade thats already turned profitable for us:
As for On Assignment, you really have to take a big step back and look at it from a distance, but the uptrend from earlier in the year has indeed, turned into a downtrend…. lower highs and lower....More>>>
Shares of Mylan (NASDAQ:MYL), an embattled branded and generic drug developer perhaps best-known for its allergic reaction injectable medication EpiPen, fell 7% in March, according to data from S&P Global Market Intelligence. Worries continue to mount for Mylan, with four f
Rheumatoid arthritis (RA) is one of the most prominent inflammatory autoimmune diseases in the world and the US, affecting an estimated 4.9 million people globally and 1.3 million Americans. First-line treatment, often a disease-modifying antirheumatic drug (DMARD), is used to reduce symptom
Has Gilead (NASDAQ:GILD) moved so far from R&D and product development within its most core franchise, HIV/AIDS, that it has forgotten to protect those crown jewels quite as thoroughly as it might? Clearly, its HIV/AIDS franchise is strong and probably getting stronger. Ye
In part 1, part 2, and part 3 of this series, I covered AbbVie's (NYSE:ABBV) immunology portfolio and growth prospects of leading oncology drugs, Imbruvica and Venclexta. In this article, I will briefly cover the potential of promising oncology drugs and technologies in AbbVie's portfolio.
I have been following Gilead Sciences (NASDAQ:GILD) for a while. Piper Jaffray's Healthcare Conference gave me the chance to reassess GILD's attractiveness. I would like to share a few thoughts about Gilead's future prospects.